Study guide

4.2 Drug Interactions in Older Adults

ANCC Gerontological Nursing Certification GERO-BC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the GERO-BC Exam 1.2 Eligibility, Fees, Scoring & Testing 1.3 How to Study for GERO-BC

2 Assessment Tools: Physical & Psychosocial

2.1 Fall, Depression & Pressure-Injury Risk Tools 2.2 Cognitive Assessment Tools (MMSE, MoCA, SLUMS, CAM) 2.3 Functional (ADL/IADL) & Pain Assessment

3 Social Determinants & Care Context

3.1 Social Determinants of Health in Aging 3.2 Caregiver & Support-System Assessment 3.3 Living Environment & Access Barriers

4 Pharmacotherapy Assessment

4.1 Polypharmacy Identification & Medication Review 4.2 Drug Interactions in Older Adults 4.3 Pharmacokinetic Changes with Aging

5 Aging Physiology & Clinical Findings

5.1 Sensory & Neurological Aging Changes 5.2 Circulatory & Cardiopulmonary Aging 5.3 Distinguishing Normal Aging from Pathology

6 Risk Factor Identification

6.1 Cognitive Impairment Risk Recognition 6.2 Non-Adherence Risk Factors 6.3 Elder Abuse & Neglect Screening

7 Evidence-Based Interventions

7.1 Evidence-Based Interventions & Expected Outcomes 7.2 Chronic Disease Management in Older Adults 7.3 Delirium Prevention & Dementia Care 7.4 Depression Care & Palliative/Hospice Care

8 Medications, Beers Criteria & Contraindications

8.1 Beers Criteria Essentials 8.2 Dosage & Route Modifications for Older Adults 8.3 Food, Drug & Herbal Contraindications

9 Care Planning & Prioritization

9.1 Nursing Diagnosis & Problem-List Evaluation 9.2 Person-Centered Care Planning 9.3 Outcome Evaluation & Plan Revision

10 Safety & Therapeutic Environment

10.1 Fall Prevention Interventions 10.2 Restraint Alternatives, Infection Control & Skin Integrity 10.3 Therapeutic Environment & Milieu Management 10.4 Wound Care Essentials for Older Adults

11 Care Coordination Across the Continuum

11.1 Transitions of Care 11.2 Case Management & Community Resources 11.3 Caregiver Support Systems

12 Theories, Prevention & Health Promotion

12.1 Theoretical Frameworks in Gerontology 12.2 Disease Prevention & Screenings 12.3 Immunizations & Preventive Care for Older Adults 12.4 Self-Management & Health Promotion Strategies

13 Communication & Adult Learning

13.1 Principles of Adult Learning 13.2 Communication Barriers & Adaptations 13.3 Patient & Family Education

14 Diversity, Ethics & Legal Practice

14.1 DEI & Older-Adult Subpopulations 14.2 Advance Directives & Surrogate Decision-Making 14.3 Ethics, Advocacy & Scope of Practice 14.4 Capacity & Informed Consent

15 Regulation, QI & Technology

15.1 CMS & Regulatory Compliance 15.2 Quality Improvement in Gerontological Settings 15.3 EHR & Documentation Standards 15.4 Telehealth, Remote Monitoring & Hospital-at-Home

4.2 Drug Interactions in Older Adults

Key Takeaways Explain This Topic AI

Older adults face higher interaction risk due to polypharmacy, multimorbidity, and reduced physiologic reserve

Pharmacodynamic interactions amplify effects at the receptor/organ level (e.g., additive sedation, bleeding, QT prolongation)

Pharmacokinetic interactions alter absorption, metabolism (CYP), or excretion and change drug exposure

High-yield pairs include warfarin–antibiotics/NSAIDs, ACEI/ARB–potassium-sparing agents, and anticholinergic or CNS-depressant stacks

  • Assessment screens for food–drug and herbal–drug interactions, not only prescription–prescription pairs
  • Last updated: August 2026

Interaction Risk in Aging

Drug interactions are a core pharmacotherapy assessment skill because older adults combine more drugs , more disease states , and less reserve to tolerate toxicity. An interaction that is trivial in a healthy middle-aged adult can precipitate hospitalization in a frail older person. GERO-BC expects you to recognize interaction patterns during assessment—not memorize every pair in a database.

Pharmacodynamic vs. Pharmacokinetic Interactions

Type Mechanism Geriatric examples

Pharmacodynamic Additive, synergistic, or antagonistic effects at target organs/receptors Two CNS depressants → sedation/falls; NSAID + anticoagulant → bleeding

Pharmacokinetic One drug changes another’s ADME (absorption, distribution, metabolism, excretion) CYP inhibitors raise substrate levels; binders reduce absorption

Pharmacodynamic interactions dominate many geriatric syndromes: stacked sedation, stacked anticholinergic burden, stacked QT prolongation, and stacked nephrotoxins. Pharmacokinetic interactions matter when narrow-therapeutic-index drugs (warfarin, digoxin, lithium, phenytoin) meet inhibitors, inducers, or renally competing agents.

  • High-Yield Drug–Drug Patterns
  • Central nervous system depression

Combining benzodiazepines, nonbenzodiazepine hypnotics (“Z-drugs”), opioids, skeletal muscle relaxants, antipsychotics, and alcohol increases risk of falls, delirium, respiratory depression, and aspiration . Assessment includes sleep aids (including OTC diphenhydramine), liquid formulations containing alcohol, and PRN anxiolytics used nightly.

Anticholinergic burden

Multiple agents with anticholinergic activity (bladder antimuscarinics, first-generation antihistamines, some antidepressants, antipsychotics, antispasmodics) produce confusion, dry mouth, constipation, urinary retention, and tachycardia . Total burden often matters more than any single agent.

Bleeding risk stacks

  • Combination Concern
  • Warfarin + NSAID / antiplatelet / SSRI ↑ GI and systemic bleeding
  • DOAC + NSAID / antiplatelet ↑ bleeding; often avoidable dual therapy
  • Antiplatelet dual therapy beyond indicated duration Excess bleed risk without clear benefit

Ask about aspirin taken for primary prevention without indication, and about fish oil / ginkgo / garlic supplements that may add antiplatelet effects.

  • Cardiovascular and electrolyte interactions
  • ACE inhibitor or ARB + potassium-sparing diuretic / potassium supplement / trimethoprim → hyperkalemia
  • ACEI/ARB + NSAID + diuretic (“triple whammy”) → acute kidney injury
  • Non-DHP calcium-channel blocker + beta-blocker → bradycardia, heart block risk
  • Digoxin + amiodarone / verapamil / clarithromycin → digoxin toxicity (PK + PD)
  • QT prolongation

Additive QT risk from macrolides, fluoroquinolones, certain antipsychotics, antiemetics (e.g., ondansetron in susceptible patients), and methadone—especially with electrolyte depletion (diuretics). Assessment notes recent antibiotics plus psychiatric meds and checks for syncope or palpitations.

Serotonergic toxicity

SSRIs/SNRIs combined with MAOIs (rare but critical), linezolid, tramadol, triptans, or St. John’s wort raise concern for serotonin syndrome —agitation, clonus, hyperreflexia, diaphoresis, fever. Older adults may present atypically; medication list review is essential when mental-status changes appear after a new serotonergic agent.

Drug–Food and Drug–Herbal Interactions

Assessment must include diet and supplements:

  • Warfarin–vitamin K consistency (not absolute avoidance): leafy greens alter INR if intake fluctuates
  • Grapefruit juice inhibits CYP3A4 → ↑ levels of some calcium-channel blockers, statins, and other substrates

Calcium / iron / magnesium / antacids bind tetracyclines, quinolones, levothyroxine, and bisphosphonates → reduced absorption if co-administered

St. John’s wort induces CYP3A4/P-gp → loss of efficacy of many drugs (including some anticoagulants and immunosuppressants)

  • Licorice root , high-dose vitamin E , and certain herbals may affect blood pressure or clotting
  • Assessment Workflow for Interactions
  • Build the complete list (Section 4.1), including OTCs and herbals
  • Flag narrow-therapeutic-index and high-risk drug classes
  • Look for additive toxicity themes (sedation, anticholinergic, bleed, QT, nephrotoxin, serotonergic)
  • Identify CYP / transporter red flags when a new antibiotic, antifungal, or amiodarone is started
  • Correlate timing: new confusion, bleed, bradycardia, or AKI after a regimen change
  • Communicate specific interaction concerns to the prescriber with clinical findings attached
  • Timing Clues

Many interaction harms appear days to weeks after a new drug is added (antibiotic + warfarin; NSAID + ACEI/diuretic). Ask: “What changed in the past two weeks?” Include stopped drugs (withdrawal) and started herbals from well-meaning family members.

Over-the-Counter Sleep and Cold Products

First-generation antihistamines in nighttime pain/sleep combinations and cold remedies add anticholinergic and sedative load that patients rarely volunteer unless asked by product name. Pair this question with fall and delirium screening whenever a new “PM” analgesic appears on the brown-bag list.

Documentation and Hand-off

When assessment uncovers an interaction risk, document:

  • The specific agents and suspected mechanism family (PD stack vs. PK exposure change)
  • The clinical finding that raises concern (INR rise, creatinine bump, falls, delirium)
  • Timing relative to regimen changes
  • Patient/caregiver understanding and any self-started OTCs or herbals

Clear hand-off prevents the next clinician from attributing the syndrome solely to “aging” or a new medical diagnosis. In transitions of care, explicitly list high-risk pairs still active at discharge.

Alcohol and Nicotine Products

Ask about alcohol quantity and pattern—even “social” intake interacts with sedatives, anticoagulants, and hepatically metabolized drugs. Nicotine replacement and smoking status can alter CYP1A2 substrates (e.g., some antipsychotics, theophylline historically). These are part of interaction assessment, not optional social history.

Exam tip: Prefer interaction mechanism families over rote lists. If the stem shows polypharmacy plus a new antibiotic, bleeding, or AKI, search for stacked PD effects or classic PK pairs before assuming primary disease alone.